Greg Rhee, PhD, FACE
Assistant Professor Adjunct, Psychiatry
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm.Bommersbach T, Olfson M, Rhee T. National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm. American Journal Of Psychiatry 2024, appiajp20230397. PMID: 38831705, DOI: 10.1176/appi.ajp.20230397.
- Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)McIntyre R, Wong S, Kwan A, Rhee T, Teopiz K, Ho R, Cao B, Mansur R, Rosenblat J, Le G. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion On Drug Safety 2024, ahead-of-print: 1-5. PMID: 38804896, DOI: 10.1080/14740338.2024.2361300.
- How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life-Years in Social Anxiety Disorder.Havlik J, Rhee T. How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life-Years in Social Anxiety Disorder. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38814116, DOI: 10.4088/jcp.23com15379.
- The role of KCNQ channel activators in management of major depressive disorderMeshkat S, Kwan A, Le G, Wong S, Rhee T, Ho R, Teopiz K, Cao B, McIntyre R. The role of KCNQ channel activators in management of major depressive disorder. Journal Of Affective Disorders 2024, 359: 364-372. PMID: 38772507, DOI: 10.1016/j.jad.2024.05.067.
- Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system.Wong S, Le G, Kwan A, Rhee T, Teopiz K, Ho R, Cao B, Rosenblat J, Mansur R, McIntyre R. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system. International Clinical Psychopharmacology 2024 PMID: 38727416, DOI: 10.1097/yic.0000000000000553.
- National trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United StatesRhee T, Bommersbach T, Rosenheck R, Nierenberg A, McIntyre R. National trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States. Journal Of Affective Disorders 2024, 358: 342-349. PMID: 38734245, DOI: 10.1016/j.jad.2024.05.044.
- Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substancesHavlik J, Rhee T, Rosenheck R. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances. PLOS ONE 2024, 19: e0302544. PMID: 38683850, PMCID: PMC11057773, DOI: 10.1371/journal.pone.0302544.
- Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysisWong S, Le G, Phan L, Rhee T, Ho R, Meshkat S, Teopiz K, Kwan A, Mansur R, Rosenblat J, McIntyre R. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 356: 684-698. PMID: 38657767, DOI: 10.1016/j.jad.2024.04.086.
- Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysisCalder C, Kwan A, Teopiz K, Wong S, Rosenblat J, Mansur R, Rhee T, Ho R, Cao B, McIntyre R. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 356: 753-762. PMID: 38636712, DOI: 10.1016/j.jad.2024.04.039.
- Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.Le G, Kwan A, Guo Z, Wong S, Badulescu S, Gill H, Teopiz K, Meshkat S, Ceban F, Phan L, Subramaniapillai M, Di Vincenzo J, Rosenblat J, Mansur R, d'Andrea G, Ho R, Rhee T, McIntyre R. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis. Acta Neuropsychiatrica 2024, 1-7. PMID: 38605630, DOI: 10.1017/neu.2024.16.
- Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic reviewSmith S, Le G, Teopiz K, Kwan A, Rhee T, Ho R, Wu J, Cao B, Ceban F, McIntyre R. Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metabolism Reviews 2024, 56: 164-174. PMID: 38655747, DOI: 10.1080/03602532.2024.2346767.
- Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic reviewLe G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.
- Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on VortioxetineKwan A, Guo Z, Ceban F, Le G, Wong S, Teopiz K, Rhee T, Ho R, Di Vincenzo J, Badulescu S, Meshkat S, Cao B, Rosenblat J, d’Andrea G, Dev D, Phan L, Subramaniapillai M, McIntyre R. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine. Advances In Therapy 2024, 41: 1983-1994. PMID: 38520501, DOI: 10.1007/s12325-024-02826-9.
- Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic reviewLeber A, Ramachandra R, Ceban F, Kwan A, Rhee T, Wu J, Cao B, Jawad M, Teopiz K, Ho R, Le G, Ramachandra D, McIntyre R. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opinion On Pharmacotherapy 2024, 25: 467-476. PMID: 38515004, DOI: 10.1080/14656566.2024.2334424.
- Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetineKwan A, Le G, Guo Z, Ceban F, Teopiz K, Rhee T, Ho R, Di Vincenzo J, Badulescu S, Meshkat S, Cao B, Rosenblat J, Dev D, Phan L, Subramaniapillai M, McIntyre R. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine. Annals Of General Psychiatry 2024, 23: 10. PMID: 38424537, PMCID: PMC10905871, DOI: 10.1186/s12991-024-00494-1.
- The Top 50 Articles and Authors of the New Millennium in Psychiatry: A Bibliometric AnalysisHavlik J, Uranga S, Lee M, Magallanes S, Wahid S, Rhee T. The Top 50 Articles and Authors of the New Millennium in Psychiatry: A Bibliometric Analysis. Cureus 2024, 16: e54762. PMID: 38523957, PMCID: PMC10961096, DOI: 10.7759/cureus.54762.
- Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023Havlik J, Wahid S, Teopiz K, McIntyre R, Krystal J, Rhee T. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Current Psychiatry Reports 2024, 26: 176-213. PMID: 38386251, DOI: 10.1007/s11920-024-01494-4.
- Comparison of industry payments to psychiatrists and psychiatric advanced practice clinicians in the USA, 2021: a cross-sectional studyHavlik J, Ososanya L, Lee M, Wahid S, Heyang M, Sun Q, Ross J, Rhee T. Comparison of industry payments to psychiatrists and psychiatric advanced practice clinicians in the USA, 2021: a cross-sectional study. BMJ Open 2024, 14: e081252. PMID: 38331855, PMCID: PMC10860012, DOI: 10.1136/bmjopen-2023-081252.
- Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-RegressionRhee T, Shim S, Manning K, Tennen H, Kaster T, d’Andrea G, Forester B, Nierenberg A, McIntyre R, Steffens D. Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression. Psychotherapy And Psychosomatics 2024, 93: 8-23. PMID: 38272009, PMCID: PMC10880806, DOI: 10.1159/000535665.
- The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysisCha D, Kleine N, Teopiz K, Di Vincenzo J, Ho R, Galibert S, Samra A, Zilm S, Cha R, d’Andrea G, Gill H, Ceban F, Meshkat S, Wong S, Le G, Kwan A, Rosenblat J, Rhee T, Mansur R, McIntyre R. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis. Expert Opinion On Pharmacotherapy 2024, 25: 5-14. PMID: 38164653, DOI: 10.1080/14656566.2023.2298340.
- Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United StatesKim S, Rhee T, Shim S. Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States. Clinical Immunology 2023, 259: 109882. PMID: 38158168, DOI: 10.1016/j.clim.2023.109882.
- The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world datad'Andrea G, Pettorruso M, Di Lorenzo G, Rhee T, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso B, Sensi S, Mansur R, Rosenblat J, Martinotti G, McIntyre R. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. Journal Of Affective Disorders 2023, 348: 314-322. PMID: 38145840, DOI: 10.1016/j.jad.2023.12.038.
- Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysisRhee T, Shim S, Popp J, Trikalinos T, Rosenheck R, Kellner C, Seiner S, Espinoza R, Forester B, McIntyre R. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Molecular Psychiatry 2023, 29: 750-759. PMID: 38123725, DOI: 10.1038/s41380-023-02366-8.
- Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary AnalysisLe G, Kwan A, Wong S, Guo Z, Teopiz K, Badulescu S, Meshkat S, d’Andrea G, Ho R, Rhee T, Cao B, Phan L, Rosenblat J, Mansur R, Subramaniapillai M, McIntyre R. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis. Advances In Therapy 2023, 41: 686-695. PMID: 38114867, DOI: 10.1007/s12325-023-02760-2.
- Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic reviewKwan A, Portnoff J, Al-Kassimi K, Singh G, Hanafimosalman M, Tesla M, Gharibi N, Ni T, Guo Z, Sonfack D, Martyniuk J, Arfaie S, Mashayekhi M, Mofatteh M, Jeremian R, Ho K, Moscote-Salazar L, Lee Á, Jawad M, Ceban F, Teopiz K, Mansur R, Ho R, Rosenblat J, Cao B, Rhee T, McIntyre R. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review. Journal Of Psychiatric Research 2023, 170: 90-110. PMID: 38134724, DOI: 10.1016/j.jpsychires.2023.12.005.